Patient with agammaglobulinemia produces anti-SARS-CoV-2 reactive T-cells after CoronaVac vaccine
暂无分享,去创建一个
[1] J. Orange,et al. New primary immunodeficiencies 2021 context and future , 2021, Current opinion in pediatrics.
[2] Mark J. Ponsford,et al. COVID-19 and X-linked agammaglobulinemia (XLA) – insights from a monogenic antibody deficiency , 2021, Current opinion in allergy and clinical immunology.
[3] L. Notarangelo,et al. Antibody responses to the SARS-CoV-2 vaccine in individuals with various inborn errors of immunity , 2021, Journal of Allergy and Clinical Immunology.
[4] Xilong Deng,et al. Protective humoral and cellular immune responses to SARS-CoV-2 persist up to 1 year after recovery , 2021, Nature Communications.
[5] Yixiao Lin,et al. Decline in neutralising antibody responses, but sustained T‐cell immunity, in COVID‐19 patients at 7 months post‐infection , 2021, Clinical & translational immunology.
[6] F. Krammer. A correlate of protection for SARS-CoV-2 vaccines is urgently needed , 2021, Nature Medicine.
[7] S. Zaffina,et al. SARS-CoV-2 Vaccine Induced Atypical Immune Responses in Antibody Defects: Everybody Does their Best , 2021, Journal of Clinical Immunology.
[8] F. Cinetto,et al. Vaccination in PADs , 2021, Vaccines.
[9] N. Freund,et al. Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity , 2021, Journal of Allergy and Clinical Immunology.
[10] Christopher A. Lazarski,et al. Robust Antibody and T Cell Responses to SARS-CoV-2 in Patients with Antibody Deficiency , 2021, Journal of Clinical Immunology.
[11] A. Fiore-Gartland,et al. Evidence for antibody as a protective correlate for COVID-19 vaccines , 2021, Vaccine.
[12] I. Quinti,et al. Clinical management of patients with primary immunodeficiencies during the COVID-19 pandemic , 2021, Expert review of clinical immunology.
[13] Mark J. Ponsford,et al. Increased Respiratory Viral Detection and Symptom Burden Among Patients with Primary Antibody Deficiency: Results from the BIPAD Study , 2020, The Journal of Allergy and Clinical Immunology: In Practice.
[14] M. Yılmaz,et al. Clinical and genetic profiles of patients with X-linked agammaglobulinemia from southeast Turkey: Novel mutations in BTK gene. , 2019, Allergologia et immunopathologia.
[15] F. Bonilla,et al. Vaccination in Primary Immunodeficiency Disorders. , 2016, The journal of allergy and clinical immunology. In practice.
[16] E. Timmers,et al. X-linked agammaglobulinemia. , 1991, Clinical immunology and immunopathology.